OPKO Health (NASDAQ:OPK) Rating Increased to Hold at StockNews.com

OPKO Health (NASDAQ:OPK) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Monday.

Other research analysts have also issued research reports about the stock. Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday.

OPKO Health Stock Up 0.6 %

NASDAQ OPK traded up $0.01 during midday trading on Monday, hitting $1.75. 29,653,360 shares of the company traded hands, compared to its average volume of 4,457,309. OPKO Health has a 52 week low of $0.86 and a 52 week high of $1.84. The company’s 50-day simple moving average is $1.55 and its 200-day simple moving average is $1.55. The company has a market cap of $1.19 billion, a PE ratio of -9.21 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. As a group, equities research analysts forecast that OPKO Health will post -0.25 earnings per share for the current year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost bought 125,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $1.59 per share, with a total value of $198,750.00. Following the transaction, the chief executive officer now directly owns 212,536,477 shares in the company, valued at approximately $337,932,998.43. The trade was a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have purchased a total of 1,389,971 shares of company stock worth $2,124,442 over the last 90 days. 47.26% of the stock is currently owned by corporate insiders.

Institutional Trading of OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of OPKO Health by 24.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company’s stock worth $1,107,000 after purchasing an additional 148,322 shares during the last quarter. Two Sigma Advisers LP increased its holdings in OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,396 shares during the period. Two Sigma Investments LP raised its position in OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after buying an additional 949,671 shares during the last quarter. ProShare Advisors LLC lifted its stake in OPKO Health by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 30,182 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in shares of OPKO Health by 42.3% in the 4th quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock valued at $2,106,000 after acquiring an additional 425,484 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.